Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review by Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge

Get full text

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway by Katherine Priest, Anh Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell, Kurtis D. Davies, Carolyn Lawrence, Emily O’Donnell, Robert C. Doebele, Liming Bao, Dara L. Aisner, Erin L. Schenk

Get full text

The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer by David Chun Cheong Tsui, MD, PhD, Douglas E. Holt, MD, Tejas Patil, MD, Alyse Staley, MS, Dexiang Gao, PhD, Brian D. Kavanagh, MD, MPH, Erin L. Schenk, MD, PhD, Chad G. Rusthoven, MD, D. Ross Camidge, MD, PhD

Get full text

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity by Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, Raphael A. Nemenoff

Get full text

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC by Tejas Patil, MD, Alyse Staley, MS, Yunan Nie, MD, Mandy Sakamoto, MD, Margaret Stalker, MD, James M. Jurica, MD, MBA, Kenna Koehler, BA, Amanda Cass, PharmD, Halle Kuykendall, BA, Emily Schmitt, MS, Emma Filar, BA, Evelina Reventaite, MS, Kurt D. Davies, PhD, Hala Nijmeh, PhD, Mary Haag, PhD, Benjamin A. Yoder, PharmD, Paul A. Bunn, MD, Erin L. Schenk, MD, PhD, Dara L. Aisner, MD, PhD, Wade T. Iams, MD, Melina E. Marmarelis, MD, D. Ross Camidge, MD, PhD

Get full text